Across TCGA pan-cancer cohorts, RNU6-614P Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated RNU6-614P data layer compared with 7 for mass-spec protein.
The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher RNU6-614P Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-614P expression acts as an unfavorable survival marker.
CESC are the cancer types where RNU6-614P Mutation most reproducibly stratifies survival.